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ABSTRACT
Objective: To conduct a validation study of 123I-N-fluoropropyl-2b-carbomethoxy-3b-
(4-iodophenyl) nortropane (123I-FP-CIT) SPECT dopaminergic imaging in the clinical diagnosis
of dementia with Lewy bodies (DLB) with autopsy as the gold standard.
Methods: Patients .60 years of age with dementia who had undergone 123I-FP-CIT imaging in
research studies and who had donated their brain tissue to the Newcastle Brain Tissue Resource
were included. All had structured clinical research assessments, and clinical diagnoses were
applied by consensus panels using international diagnostic criteria. All underwent 123I-FP-CIT
imaging at baseline, and scans were rated as normal or abnormal by blinded raters. Patients were
reviewed in prospective studies and after death underwent detailed autopsy assessment, and
neuropathologic diagnoses were applied with the use of standard international criteria.
Results: Fifty-five patients (33 with DLB and 22 with Alzheimer disease) were included. Against
autopsy diagnosis, 123I-FP-CIT had a balanced diagnostic accuracy of 86% (sensitivity 80%,
specificity 92%) compared with clinical diagnosis, which had an accuracy of 79% (sensitivity
87%, specificity 72%). Among patients with DLB, 10% (3 patients) met pathologic criteria for
Lewy body disease but had normal 123I-FP-CIT imaging.
Conclusions: This large autopsy analysis of 123I-FP-CIT imaging in dementia demonstrates that it
is a valid and accurate biomarker for DLB, and the high specificity compared with clinical diag-
nosis (20%higher) is clinically important. The results need to be replicated with patients recruited
from a wider range of settings, including movement disorder clinics and general practice. While an
abnormal 123I-FP-CIT scan strongly supports Lewy body disease, a normal scan does not exclude
DLB with minimal brainstem involvement.
Classification of evidence: This study provides Class I evidence that 123I-FP-CIT dopaminergic
neuroimaging accurately identifies patients with DLB. Neurology® 2017;88:276–283
GLOSSARY
AD 5 Alzheimer disease; CBD 5 corticobasal degeneration; CERAD 5 Consortium to Establish a Registry for Alzheimer’s
Disease; CI 5 confidence interval; DLB 5 dementia with Lewy bodies; FTLD 5 frontotemporal lobar degeneration;
123I-FP-CIT 5 123I-N-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl) nortropane; LBD 5 Lewy body disease; RBD 5
REM sleep behavior disorder; PD 5 Parkinson disease; UPDRS 5 Unified Parkinson’s Disease Rating Scale.
Early identification and accurate diagnosis of dementia are priorities because disease-modifying
treatments need to be administered at the earliest stage. Accurate diagnosis is more difficult during
earlier phases of disease, and the need to use biomarkers to improve accuracy is correspondingly
more pressing and included in recent diagnostic criteria.1,2 For example, dementia with Lewy
bodies (DLB) is the second commonest cause of degenerative dementia after Alzheimer disease
(AD).3 Diagnostic criteria for DLB have high accuracy in specialist centers (sensitivity and
specificity both .80%),4 although case detection in many centers is less accurate.
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Dopaminergic neurons in the substantia
nigra pars compacta project to the striatum
(the nigrostriatal pathway). Their loss is associ-
ated with the presence of a-synuclein aggre-
gates (Lewy bodies and Lewy neurites), which
are a core neuropathologic feature of DLB and
Parkinson disease (PD).4 Autopsy studies
report a loss of dopamine transporters associ-
ated with loss of nigrostriatal neurons,5 which
can be assessed with imaging. Such imaging,
using PET and SPECT ligands, is abnormal
in PD, multiple system atrophy, corticobasal
degeneration (CBD),6 progressive supranuclear
palsy,6 frontotemporal lobar degeneration
(FTLD),7 and DLB.8 Dopaminergic neuroi-
maging is a biomarker included as a suggestive
feature in the consensus diagnostic criteria
for DLB,4 and a review of 123I-N-fluoropropyl-
2b-carbomethoxy-3b-(4-iodophenyl) nortro-
pane (123I-FP-CIT) SPECT studies, with clinical
diagnosis used as the standard, reported a sensi-
tivity of 78% and specificity of 90% for differ-
entiating AD from DLB.9
Although 123I-FP-CIT imaging has good
accuracy for DLB in degenerative dementia, its
validation has restedmainly on comparisons with
a consensus clinical diagnosis.10 The gold
standard for biomarker validation is autopsy,
but only 2 small studies have evaluated
123I-FP-CIT against neuropathology in DLB.
One examined 20 patients (8 with DLB) and
found that 123I-FP-CIT had a sensitivity of
88% and specificity of 100%.11 The other inves-
tigated neuronal loss and pathology in 23 cases
(7 with DLB), reporting an association between
neuronal density in the substantia nigra and
reduced uptake on 123I-FP-CIT.12 There is there-
fore a need to validate 123I-FP-CIT diagnostic
accuracy in autopsy-confirmed DLB. Here, we
report such a validation using brain tissue from
the Newcastle Brain Tissue Resource in 55
patients with dementia who had 123I-FP-CIT
SPECT imaging in research studies during life.
METHODS The primary purpose of this study was to assess
the diagnostic accuracy of 123I-FP-CIT dopaminergic imaging
in people with neurodegenerative dementia. This study provides
Class I evidence that 123I-FP-CIT dopaminergic neuroimaging
accurately identifies patients with DLB.
Patients and clinical diagnosis. Patients .60 years old (at
clinical assessment) in the Newcastle Brain Tissue Resource who
had had 123I-FP-CIT imaging in the context of a dementia were
included in this study. We did not include patients with PD or
healthy controls.
Standard protocol approvals, registrations, and patient
consents. Clinical research studies were approved by local research
ethics committees and the UK Department of Health Administra-
tion of Radioactive Substances Advisory Committee. Participants
gave written informed consent; if they were not competent, assent
was obtained from their nearest relative. At death, the relative gave
permission for tissue donation and use of autopsy material and pre-
vious clinical data for research in accordance with research ethics
committee procedures for Newcastle Brain Tissue Resource.
Individuals were recruited from memory and dementia serv-
ices where they received clinical diagnoses from board-certified
psychiatrists or neurologists. They participated in prospective
studies of dementia at Newcastle University or University College
London. All undertook structured research assessments and had
123I-FP-CIT SPECT imaging. These studies took place from
the late 1990s through the first decade of this millennium, and
clinical diagnostic criteria evolved over this time. Most patients
were assessed with the 1996 consensus criteria for DLB,13 but
some were assessed with the 2005 criteria.4 The latter criteria were
modified in that 123I-FP-CIT was not used for clinical diagnosis
of patients for this analysis, and all clinical (and pathologic)
diagnoses were applied blinded to 123I-FP-CIT findings. Patients
with AD met the National Institute of Neurological and
Communicative Disorders and Stroke–Alzheimer’s Disease and
Related Disorder Association criteria for AD.14
Patients underwent structured clinical assessments and neuro-
cognitive testing, including the Mini-Mental State Examination15
and Cambridge Cognitive Examination.16 Parkinsonism was
assessed with the motor subsection of the Unified Parkinson’s
Disease Rating Scale (UPDRS).17 Assessments were repeated
annually until patients could no longer comply, and final assess-
ments nearest to death were recorded for this analysis.
123I-FP-CIT SPECT imaging. With the use of a previous imag-
ing protocol,18 Newcastle patients were scanned for 30 minutes with
a triple-head gamma camera (Picker 3000XP), 4 hours after injection
of 150 MBq of 123I-FP-CIT (DaTSCAN, GE Healthcare, Chalfont
St. Giles, UK). In London, acquisition was 30 to 45 minutes with
a brain-dedicated StrichmanMedical Equipment 810 gamma camera
3 to 4 hours after injection (185 MBq).8
After reconstruction, scans were visually rated at each site by
independent raters (5 in Newcastle, 3 in London) blinded to clin-
ical information, and a consensus rating of either abnormal (con-
sistent with Lewy body disease [LBD]) or normal was agreed on,
as previously reported.18,19
Neuropathology. Cases were independently assessed neuropa-
thologically by researchers blinded to clinical and 123I-FP-CIT
findings.20 The right hemisphere, brainstem, and cerebellum were
fixed in 4% buffered aqueous formaldehyde for 4 to 6 weeks.
Sections from paraffin-embedded blocks from frontal, temporal,
parietal, and occipital cortices; cingulate and hippocampus;
striatum (including both caudate nucleus and putamen);
amygdala; midbrain; and locus coeruleus were cut at 6 mm and
mounted on 4% 3-aminopropyltriethoxysilane–coated slides.20
Immunostaining with monoclonal antibodies against hyperphos-
phorylated tau (AT8, dilution 1:4,000, Innogenetics, Ghent,
Belgium), b-amyloid (4G8, dilution 1:15,000, 4G8, Signet
Laboratories, Inc, Dedham, MA), and a-synuclein (dilution 1:200,
Chemicon, Hofheim, Germany) was carried out. Before this, slides
were microwaved for antigen retrieval in 0.01 mL citrate buffer for
10 minutes (AT8), pressure cooked in 0.01 mol/L EDTA for 90
seconds (a-synuclein), or immersed for 1 hour in formic acid (4G8).
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Immunopositivity was assessed with a MenaPath horseradish perox-
idase polymer detection kit (Menarini Diagnostics, Berkshire, UK)
with chromogen 3,3 diaminobenzidine and counterstained with
hematoxylin. Finally, tissue was dehydrated through an alcohol series,
cleared, and mounted with DPX (CellPath, Powys, UK).20
Neuropathologic diagnoses were assigned with the use of
accepted international neuropathologic criteria, including neu-
ritic Braak stages,21 Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) scores,22 and Newcastle- McKeith
criteria.4 Of note, AD was diagnosed if neuritic Braak stages were
V or VI and CERAD scores were B or C. We diagnosed AD if
neuropathologic findings indicated a “high probability of AD”
(according to National Institute on Aging–Reagan Institute cri-
teria) and when Thal b-amyloid phases were available (total n 5
17; AD n 5 9 including 5 mixed AD/DLB) a “high AD neu-
ropathologic change” (according to National Institute on Aging–
Alzheimer’s Association criteria).
A final clinicopathologic diagnosis was applied, combining avail-
able data from the clinical research and health service records with this
neuropathologic assessment but not including results of the
123I-FP-CIT imaging. It is common for older people to have more
than one neuropathology contributing to their dementia. Here, the
term mixed LBD1 AD is used to classify patients who fulfilled the
neuropathologic criteria for both DLB (limbic/neocortical LBD) and
AD (Braak stage V/VI and CERAD B/C).20 These final clinicopath-
ologic diagnoses were used to validate the 123I-FP-CIT results.
Statistical analysis. The Statistical Package for Social Sciences
software (SPSS version 23) was used for statistical evaluation.
For group comparisons, x2 tests were used for categorical varia-
bles, and for continuous variables, we tested for normality of
distribution with t tests or Mann-Whitney tests. Diagnostic
accuracy of 123I-FP-CIT (sensitivity, specificity, and overall
accuracy) against autopsy was calculated from standard 2 3 2
frequency tables, and 95% confidence for these was calculated
with Minitab (version 16.1).
RESULTS At baseline 123I-FP-CIT, there were 33
patients with DLB and 22 patients with AD (see table
1 for details and figure 1). There were no group differ-
ences in sex, but patients with AD were older at
death. In most cases, the neuropathologic diagnoses
confirmed the clinical baseline diagnoses; 70% of
DLB cases had pure LBD, and 73% of AD cases
had pure AD, with a few patients having LBD 1
AD at autopsy (3 with DLB, 4 with AD). Three
patients (1 with clinical DLB, 2 with AD) had FTLD
with no other significant neuropathology, and one
patient with DLB had CBD. Table 2 details clinical
features. Groups were similar in cognition at baseline
and final assessments, and as expected, there was
more parkinsonism in the DLB group at both time
points. Patients with DLB also had more depression,
although levels were not clinically significant. The
proportion of patients with core features of DLB
was similar to that in previously published studies.
Most patients were assessed before the 2005 criteria,
so ascertainment of REM sleep behavior disorder
(RBD) was limited, but 6 patients with DLB had
RBD. No patients had neuroleptic sensitivity, but
very few had been exposed to such medication.
Autopsy validation of 123I-FP-CIT imaging. To assess the
validity of 123I-FP-CIT for detecting LBD in the con-
text of dementia, all cases with either pure LBD or
mixed LBD 1 AD (n 5 30) were regarded as having
proven LBD, and all other cases were classified as
non-LBD (n 5 25: 21 with AD, 3 with FTLD, 1
with CBD). Of the 30 LBD cases, 24 had abnormal
123I-FP-CIT imaging (sensitivity 80%, 95%
confidence interval [CI] 92–62), and of the 25 non-
LBD cases, 23 had normal 123I-FP-CIT imaging
(specificity 92%, 95% CI 99–74). Balanced
diagnostic accuracy was 86% (95% CI 94–74).
Accuracy of clinical diagnosis. We compared the diag-
nostic accuracy of clinical diagnosis (blinded to
123I-FP-CIT) at the time of 123I-FP-CIT imaging vs
autopsy diagnosis. Of the 30 autopsy LBD cases, 26
were diagnosed clinically as having DLB and 4 were
Table 1 Demographic and pathologic data by baseline clinical diagnosis
DLB (n 5 33) AD (n 5 22)
Age at 123I-FP-CIT, y 75.6 (7.2) 78.9 (6.9) t 5 1.71, df 5 55, p 5 0.09
Age at death, y 78.8 (6.8) 86.0 (6.8) t 5 3.84, df 5 53, p , 0.001
M:F, n 21:12 13:9 x2 5 0.116, df 5 1, p 5 0.734
Interval between 123I-FP-CIT and death, y 3.3 (2.3) 7.1 (3.5) U 5 606, p , 0.001
Interval between last assessment and death, mo 12.3 (11.2) 34.9 (32.2) U 5 538, p , 0.001
Neuropathologic findings at autopsy, n
LBD 23 0
AD 5 16
Mixed LBD and AD 3 4
Frontotemporal lobar degeneration 1 2
Corticobasal degeneration 1 0
Abbreviations: AD 5 Alzheimer disease; DLB 5 dementia with Lewy bodies; 123I-FP-CIT 5 123I-N-fluoropropyl-2b-
carbomethoxy-3b-(4-iodophenyl) nortropane; LBD 5 Lewy body disease.
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clinically diagnosed as having AD (sensitivity 87%,
95% CI 96–70). Of the 25 non-LBD cases, 18 were
diagnosed as having AD and 7 as having DLB
(specificity 72%, 95% CI 88–51). Balanced
diagnostic accuracy was 79% (95% CI 89–66).
To assess possible reasons for misleading
123I-FP-CIT scan results, we re-examined all clinical
records, research records, and autopsy findings for the
8 clinically misclassified cases, 2 false positives and 6
false negatives (see figure e-1 at Neurology.org for
examples). Both false-positive cases had been diag-
nosed as DLB, and the 123I-FP-CIT scans were
reported as abnormal by all blinded raters. One had
parkinsonism (UPDRS score 5 33) and cognitive
fluctuations. Neuropathologically, this case had
FTLD with no LBD or AD pathology, including
no a-synuclein pathology in the substantia nigra
but considerable reduction in overall nigral volume,
which may have contributed to the parkinsonism and
abnormal 123I-FP-CIT. The other case (figure 2) had
all 3 core features of DLB (UPDRS score 5 13) and
pathologically had AD. Again, there was no evidence
of a-synuclein pathology in the substantia nigra or in
the striatum, but there were abundant neurofibrillary
Figure 1 Flowchart showing relationship of clinical diagnosis to autopsy and 123I-FP-CIT imaging findings
123I-FP-CIT 5 123I-N-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl) nortropane.
Table 2 Clinical features of study participants
DLB (N 5 33) AD (N 5 22)
MMSE score at 123I-FP-CIT 17.9 (6.2) 19.3 (5.8) t 5 0.834, df 53, p 5 0.41
MMSE score nearest death 11.9 (9.4) 14.0 (5.9) U 5 277, p 5 0.57
CAMCOG score at 123I-FP-CIT 60.1 (20.2) 61.8 (18.8) t 5 0.317, df 49, p 5 0.75
CAMCOG score nearest death 43.0 (28.8) 47.8 (21.6) t 5 0.255, df 3, p 5 0.82
UPDRS score at 123I-FP-CIT 21.7 (13.5) 5.7 (5.7) U 5 100, p , 0.001
UPDRS score nearest death 31.8 (13.2) 15.0 (12.2) t 5 3.87, df 38, p , 0.001
Geriatric Depression Scale score at 123I-FP-CIT 4.1 (2.3) 2.8 (2.3) t 5 1.98, df 49, p 5 0.05
Geriatric Depression Scale score nearest death 5.7 (4.0) 2.8 (3.0) t 5 2.42, df 33, p 5 0.02
Core features of DLB, n (%)
Fluctuating cognition 27 (82) 5 (23)
Recurrent visual hallucinations 29 (88) 1 (5)
Spontaneous parkinsonism 23 (70) 2 (9)
Medication at baseline, n, %
Antidementia 9 (27) 2 (9)
Antiparkinsonian 8 (24) 0 (0)
Antipsychotic 3 (9) 3 (14)
Antidepressant 5 (15) 3 (14)
Abbreviations: AD5 Alzheimer disease; CAMCOG5 Cambridge Cognitive Examination; DLB5 dementia with Lewy bodies;
123I-FP-CIT 5 123I-N-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl) nortropane; MMSE 5 Mini-Mental State Examina-
tion; UPDRS 5 Unified Parkinson’s Disease Rating Scale.
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tangles in the nigra without severe neuronal loss. Nei-
ther case had sufficient pathology in the striata to
account for the abnormal scans. Both of these cases
had severe dementia at the time of baseline assessment
(Mini-Mental State Examination scores of 9 and 11)
and died 1 and 2 years after study entry, thereby
precluding repeated longitudinal assessments.
Of the 6 false-negative cases, 3 had a clinical base-
line diagnosis of AD and had mixed LBD 1 AD
pathology at autopsy. In all cases, at baseline, they
had no parkinsonism, one had possible visual halluci-
nations only, and one had possible cognitive fluctua-
tions. Neither of these symptoms was regarded by the
consensus clinical raters as sufficient evidence of
a symptom to support DLB, so both were classified
as pure AD cases clinically. They lived 6, 10, and 11
years after baseline assessment. During this time, one
patient developed parkinsonism (last UPDRS score 5
36) and complex visual hallucinations, and one devel-
oped parkinsonism (no UPDRS score recorded) in
addition to the possible visual hallucinations. At
autopsy, both showed moderate neuronal loss in the
substantia nigra. The third patient developed mild
parkinsonism (UPDRS score 5 13), auditory hallu-
cinations, and paranoid delusions, with mild nigral
neuron loss at autopsy. The other 3 false-negative
cases all met consensus criteria for probable DLB at
the time of 123I-FP-CIT, having complex visual hal-
lucinations and marked cognitive fluctuations, and
neuropathologically fulfilled the criteria for DLB,
Figure 2 Photomicrographs of typical 123I-FP-CIT–positive, false-negative, and false-positive cases
Photomicrographs illustrating a case with clinical dementia with Lewy bodies (DLB) and abnormal (positive) 123I-N-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl)
nortropane (123I-FP-CIT) scan with marked neuronal dopaminergic cell loss in the substantia nigra (SN) (A) and Lewy bodies in the SN (D) and temporal
cortex (G). A false-negative 123I-FP-CIT scan in an individual with clinical and pathologic dementia with Lewy bodies but only mild cell loss (B) and
a-synuclein pathology of low severity in the SN (E) and moderate severity in the temporal cortex (H). A false-positive 123I-FP-CIT scan in an individual
with clinical and pathologic Alzheimer disease virtually without dopaminergic cell loss in the SN (C) and no a-synuclein pathology in the SN (F) or temporal
cortex (I). Scale bar in panel A represents 200 mm and is valid for panels A–F; scale bar in panel G represents 50 mm and is valid for panels G–I. For the
dopaminergic neurons, cresyl fast violet was used. For the a-synuclein immunohistochemistry, Novocastra antibody (1:200 dilution) was used with
hematoxylin as counterstain.
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with up to moderate nigral neuron loss at autopsy (see
figure 2 for example). Of these cases, 2 had mild
parkinsonism (UPDRS scores 15 and 17), while the
third had moderate parkinsonism (UPDRS score 5
28). Full neuropathology details of all cases are avail-
able in table e-1.
DISCUSSION In this large clinical/imaging/pathologic
validation study, we found that 123I-FP-CIT imaging
had very good diagnostic accuracy (86%, sensitivity
80%, specificity 92%) for distinguishing DLB from
AD. These figures are similar to those reported in
clinical studies of 123I-FP-CIT in DLB,9 in which
a consensus diagnosis from a panel of 3 to 5 experts
was used as the gold standard. This suggests that this
method of validation of diagnosis, at a time when
autopsy is not possible, is indeed valid.
The value of a test depends on its setting. For
screening in large populations, a high sensitivity is
crucial, but for specialist settings, for diagnostic tests
such as 123I-FP-CIT, it is more important to have
a high specificity; a specificity of .80% has been
suggested.23 The 92% specificity achieved strongly
supports the value of 123I-FP-CIT imaging in distin-
guishing DLB from AD, but it is important to note
that abnormal 123I-FP-CIT imaging also occurs in
FTLD7 and other neurologic conditions such as
progressive supranuclear palsy and CBD,8 so the
accuracy reported here does not necessarily apply
in other settings.
The value of a test also depends on how much it
adds to clinical diagnosis. Here, the substantially
larger specificity compared with clinical diagnosis
(92% vs 72%) is important. However, such conclu-
sions need to be interpreted in the context of the wide
CIs for our findings. Furthermore, while 123I-FP-CIT
accuracy is consistent across centers, this is not the
case for clinical diagnosis, especially for DLB; 4.2% of
cases of DLB are diagnosed in the community vs
7.2% in secondary care,3 and our clinical diagnostic
rates are higher than in other secondary care settings
(8% vs 2%).24 Thus, in our specialist centers, the
additional value of 123I-FP-CIT imaging for improv-
ing diagnosis is likely to be less than would be ex-
pected in other settings with lower diagnosis rates.
However, decisions about using expensive imaging
assessments in primary care need to be carefully bal-
anced against the potential benefits.
It is important to note that the patients in this
study were derived from secondary dementia services.
Hence, our findings should not be generalized to set-
tings such as movement disorder services or primary
care. Patients were also assessed as having a neurode-
generative pattern of dementia, and we did not
include patients with significant cerebrovascular dis-
ease. However, our findings are relevant for situations
in which 123I-FP-CIT imaging is typically used,
namely when clinical assessment indicates a neurode-
generative cause.
Two false-positive cases were clinically DLB. Both
had moderate to severe dementia at baseline, perhaps
limiting the accuracy of clinical assessment. In one
case, FTLD may have led to neuronal loss in the sub-
stantia nigra and explained the abnormal
123I-FP-CIT, as has been reported previously.7 The
other case provides no pathologic explanation for
the abnormal 123I-FP-CIT. Three false-negative cases
had AD at the time of 123I-FP-CIT but lived several
years and developed symptoms characteristic of DLB
and thus may have developed LBD later. The other 3
appear to be genuine false-negative cases whose LBD
may have been predominantly limbic and neocortical
at presentation, further suggested by at worst only
moderate neuronal loss in the substantia nigra at
autopsy. All 3 had prominent visual hallucinations
and cognitive fluctuations. Thus, 3 of 33 (10%) of
the DLB cases could not have been diagnosed with
123I-FP-CIT at the time of the initial assessment. The
presence of DLB without detectable dopaminergic
deficits on 123I-FP-CIT imaging is consistent with
previous reports showing synucleinopathy in limbic
and neocortical areas (most frequently in the amyg-
dala and olfactory lobe) when only little or no such
pathology is found in the substantia nigra.25,26 It is
important to remember that while the high specificity
of 123I-FP-CIT means an abnormal scan strongly sup-
ports DLB, a normal scan occurs in a proportion of
people with DLB, here 10%, and does not exclude
DLB. 123I-FP-CIT imaging is not a direct marker of
synuclein pathology but only a measure of its effect on
neurons, which can be damaged by other pathology, as
occurred here in the false-positive case with FTLD.
The clinical accuracy of our study does not fully
reflect present practice. Most cases were diagnosed
with the use of 1996 rather than 2005 criteria. All
patients with DLB with RBD had an abnormal
123I-FP-CIT scan and LBD pathology, which,
although numbers are small, is consistent with reports
that the inclusion of RBD improves the diagnosis of
DLB.27 This suggests that if we had missed such pa-
tients, then their inclusion might have further
improved the sensitivity. A more important limitation
of our study is the gap between 123I-FP-CIT and
autopsy, which was greater in those with AD. Pre-
vious autopsy studies have reported similar findings,
i.e., that patients with DLB come to autopsy more
quickly,27 consistent with their higher mortality.28
However, such a difference would seem more likely
to reduce the diagnostic accuracy of 123I-FP-CIT. It is
estimated that it takes at least 5 years to develop LBD
sufficient to cause clinical symptoms,29 and longer-
lived patients with AD might develop DLB and thus
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become false-negative scan patients. Indeed, this is
what appears to have happened with some study pa-
tients. On the other hand, longer-lived patients with
DLB with abnormal scans who developed AD would
remain true-positive patients. We should add that this
study has important strengths: patients were recruited
from experienced DLB centers by clinicians skilled in
clinical diagnosis, 123I-FP-CIT imaging, and neuropa-
thology, and we have a sample size much larger than
in the 2 small previous reports (whose patients were
also included in this study).
We report the largest autopsy study examining the
neuropathologic diagnoses in patients who had
undergone 123I-FP-CIT imaging in the context of
dementia. Although our findings need replication
in other centers and in future prospective studies,
123I-FP-CIT is a valid biomarker of DLB with high
sensitivity and specificity. This strongly supports the
use of 123I-FP-CIT dopaminergic imaging in the diag-
nosis of DLB.
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